Papatheodoridis, G. V. Et Al. 2018. Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort. AASLD 2018 .

Papatheodoridis, G. V., Dalekos, G. N., YURTAYDIN, S. C., Sypsa, V., van Bömmel, F., Buti, M., ... Calleja, J. L.(2018). Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort . AASLD 2018

Papatheodoridis, George Et Al. "Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort," AASLD 2018, 2018

Papatheodoridis, George V. Et Al. "Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort." AASLD 2018 , 2018

Papatheodoridis, G. V. Et Al. (2018) . "Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort." AASLD 2018 .

@conferencepaper{conferencepaper, author={George V Papatheodoridis Et Al. }, title={Prediction and Need for Surveillanceof Hepatocellular Carcinoma (HCC)Development after the First 5 Years of Entecavir(ETV) or Tenofovir Disoproxil Fumarate (TDF)Therapy in Caucasian Chronic Hepatitis B(CHB) Patients of the PAGE-B Cohort}, congress name={AASLD 2018}, city={}, country={}, year={2018}}